Clopidogrel Use in CYP2C19 Loss-of-Function Carriers With High Bleeding Risk After Percutaneous Coronary Intervention
CONCLUSIONS: Among patients with HBR, clopidogrel use in CYP2C19 LOF carriers was significantly associated with increased ischemic events after PCI.PMID:36792180 | DOI:10.1253/circj.CJ-22-0826
Source: Circulation Journal - Category: Cardiology Authors: Yuichi Sawayama Yukinori Tomita Soji Kohyama Yosuke Higo Kenji Kodama Kohei Asada Noriaki Yagi Megumi Fukuyama Atsushi Hayashi Wataru Shioyama Hiroshi Sakai Tomoya Ozawa Tetsuichiro Isono Daiki Hira Takashi Yamamoto Shin-Ya Morita Yoshihisa Nakagawa Source Type: research
More News: Academia | Angioplasty | Bleeding | Cardiology | Cardiovascular | Clopidogrel | Coronary Angioplasty | Heart | Heart Attack | Ischemic Stroke | Percutaneous Coronary Intervention | Plavix | Stroke | Study